Nanotechnology in Cancer Treatment: The Future is Now

by

Despite the advances in the field of molecular biology, cancer continues to be one of the most significant problems in contemporary medicine due to the relatively simple and still not fully understood biological nature of cancer and its variety. Conventional treatments of cancer, including chemotherapy and radiotherapy, are notorious for being associated with hostile effects and small effectiveness, particularly at later stages of growth. However, there are new trends in the development of nanotechnologies that are changing the appearance of cancer treatment flows. Taking advantage of the characteristics of nanoparticles, new therapies are being designed that are more effective, less toxic, and therefore beneficial to the patient. The present article focuses on the advanced uses of nanotechnology in cancer therapy and the ability of this technology to revolutionize therapy for one of humanity’s top killers.

The Promise of Nanoparticles in Cancer Therapy

Nanoparticles are simply very small particles with sizes varying from 1 to 100 nanometers. Nanoparticles are very small in size, and they possess specific physical and chemical characteristics; thus, they can be designed to release pharmaceuticals specifically to cancer cells. This targeted delivery decreases the harm to the normal tissues, thus lessening the side effects inherent to most traditional cancer treatments.

Nanoparticulate drug delivery systems have some advantages, among which one of the most important is improving the solubility and stability of the anticancer drugs. Most chemotherapeutic agents are lipophilic, and this presents problems in their preparation for administration. The drugs can be encapsulated in nanoparticles such that they enhance their bioavailability and get to the tumor site in an active state.

Metallic Nanoparticles: Gold and Silver

Both gold and silver nanoparticles have been used widely in cancer research because of the biocompatibility of the metal and the ease with which functional groups can be attached to them. These nanoparticles can be made in such a way that they can home in on cancer cells and deliver the desired dose of medication. Scholars have looked into the probability of increasing cancer chemotherapeutic drugs’ efficiency and creating new phototherapeutic approaches based on gold nanoparticles. Photothermal therapy utilizes nanoparticles of gold; on illumination with light, these particles convert light energy into heat, which destroys cancerous cells without damaging the adjacent healthy tissues.

Silver nanoparticles, on the other hand, show different strong antimicrobial activities and have been studied with different combination therapies. Multi-modal treatments are planned by incorporating silver nanoparticles as a drug delivery system with other anticancer agents to overcome drug resistance.

Yearwise Publication Trend on “nanotechnology”

Find publication trends on relevant topics

Lipid-Based Nanoparticles

Another group of nanocarriers for cancer treatment are lipid-based ones, such as liposomes and solid lipid nanoparticles. Liposomes are small, round structures with phospholipid bilayers through which either hydrophilic or hydrophobic drugs can be surrounded. These virtues make them suitable for transporting a broad spectrum of anticancer drugs to the tumor site and destroying malignant cells efficiently. Contrary to cancer cells, liposomes can be functionalized with targeting ligands to increase their interaction and binding to the tumor cells, hence improving the therapeutic ratio.

SLNs are spherical particles formed and stabilized with a solid lipophilic core surrounded by a phospholipid monolayer. They have interesting features like the ability to deliver a controlled amount of a drug slowly, they have a large loading capacity for the drug, and they are stable. SLNs have been investigated for the delivery of diversified chemotherapeutic agents, like paclitaxel and doxorubicin, where it has even been seen that there is increased effectiveness and reduced side effects as compared to other formulations.

Polymeric Nanoparticles

Polymeric nanoparticles are prepared from biocompatible and biodegradable polymers, which makes them ideal for long-term and regulated release of the drug. These nanoparticles can be designed to be sensitive to particular changes in the physiological environment, for instance, pH or the activity of a certain enzyme, and the drug will only be released at the tumor site. This specific distribution system minimizes the general toxic effects when intervening with the treatment’s curative effects.

Several studies have shown that polymeric nanoparticles can be effective in combating this issue of MDRA, which is a major concern in cancer treatments. Polymeric nanoparticles can be designed to co-deliver both chemotherapeutic drugs and gene-silencing agents that, when internalized by the cancer cells, will block the drug efflux mechanism and, at the same time, induce cancer cell apoptosis thus overcoming drug-resistant tumors.

Nanoparticle-Based Combination Therapies

The use of more than one therapeutic modality at the same time or using products that have established therapeutic properties is regarded as combination therapy, and this strategy occupies an important position in the current model of cancer treatment. Multi-drug encapsulation is also possible using nanoparticles, due to their ability to release the drugs with different modes of action all at once. This approach goes further to improve the effectiveness of the therapy and lessen the chances of medication resistance.

A case in point is the employment of nanoparticles for the co-delivery of docetaxel as well as doxorubicin, two effective chemotherapeutic drugs. When these drugs are incorporated in a single nanoparticle, the researchers have found a way of achieving the desired synergistic ratio, hence enhancing the targeting of tumors and minimizing the side effects. Also, targeted drug delivery can be attained through the incorporation of targeting ligands into the nanoparticles, thus increasing the nanoparticle’s specificity to the cancer cells, which is very convenient since it ensures that the therapeutic agents are delivered only to the intended area.

Nanoparticles in Immunotherapy

Immunotherapy is one of the developing approaches in the treatment of cancer that involves the use of the immune system of the body to identify and eliminate cancerous cells. Immunotherapy can be made more effective by the use of nanoparticles to boost the delivery and presentation of the antigens to the immune cells. For example, they can be designed to deliver tumor antigens and adjuvants, which trigger a powerful response against cancer cells.

The innovations in cancer treatment have involved designing nanoparticles that can alter the tumor microenvironment in a manner that is favorable for the infiltration and effectiveness of immune cells. Nanoparticle-based immunotherapies take strategic approaches of targeting immune checkpoints to release immune-stimulatory agents to reverse the immunosuppressive tumor microenvironment of cancer to improve the efficacy of cancer immunotherapy.

Recent Publications on “nanotechnology”

Find publications on relevant topics

Challenges and Future Directions

However, there are several challenges regarding the clinical application of nanoparticle-mediated cancer therapeutic strategies. The biology of the cancer is relatively intricate, combined with the difficulties that arise when designing a standard regimen given the differences in the patient’s response to the treatment cycles. Furthermore, the chronic safety and genotoxicity properties of nanoparticles need to be assessed through extensive in vitro and in vivo research tests.

In future investigations, the details of the nanoparticle design and its sentimental action will be on the rise to enhance the targeting ability and the therapeutic action of the nanoparticles. Combined with image-guided therapies such as nanoparticle-based therapies, patients can have a real-time outlook on the progression of the disease and make desirable changes in the course of the therapy. Furthermore, researchers have identified the possibilities of using multifunctional nanoparticles for the targeted delivery of drugs, genes, and imaging agents for cancer therapy.

Conclusion

Nanotechnology has the potential to dramatically transform the approach to cancer care through the application of advanced therapies that are precise, effective, and tailored to an individual’s needs. The characteristics of nanoparticles have the potential to accurately target the therapeutic agents to the affected areas with reduced side effects and improved results. As discoveries for new uses for nanoparticles are made and applications are fine-tuned, it is envisioned that targeted cancer therapies involving nanoparticles would be one of the basic facets of most comprehensive cancer management for patients around the globe.

References

  1. Neha Desai, Momin M, Khan T, Gharat S, Ningthoujam RS, Omri A. Metallic nanoparticles as drug delivery system for the treatment of cancer. Expert Opin Drug Deliv. 2021 Sep;18(9):1261-1290. doi: 10.1080/17425247.2021.1912008. Epub 2021 Apr 14. PMID: 33793359.
  2. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020 Aug 20;7:193. doi: 10.3389/fmolb.2020.00193. PMID: 32974385; PMCID: PMC7468194.
  3. Li K, Zhan W, Chen Y, Jha RK, Chen X. Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer. Front Pharmacol. 2019 Dec 18;10:1436. doi: 10.3389/fphar.2019.01436. PMID: 31920642; PMCID: PMC6930690.
  4. He, M.H., Chen, L., Zheng, T., Tu, Y., He, Q., Fu, H.L., Lin, J.C., Zhang, W., Shu, G., He, L. and Yuan, Z.X., 2018. Potential applications of nanotechnology in urological cancer. Frontiers in Pharmacology, 9, p.745.
  5. Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J, Peer D. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020 Nov 18;6(47):eabc9450. doi: 10.1126/sciadv.abc9450. PMID: 33208369; PMCID: PMC7673804.
  6. Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168. PMID: 29978216; PMCID: PMC6233779.
  7. Altwaijry N, Somani S, Parkinson JA, Tate RJ, Keating P, Warzecha M, Mackenzie GR, Leung HY, Dufès C. Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Deliv. 2018 Nov;25(1):679-689. doi: 10.1080/10717544.2018.1440666. PMID: 29493296; PMCID: PMC6058574.
  8. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol Biosci. 2020 Aug 20;7:193. doi: 10.3389/fmolb.2020.00193. PMID: 32974385; PMCID: PMC7468194.
  9. Turanli B, Grøtli M, Boren J, Nielsen J, Uhlen M, Arga KY, Mardinoglu A. Drug Repositioning for Effective Prostate Cancer Treatment. Front Physiol. 2018 May 15;9:500. doi: 10.3389/fphys.2018.00500. PMID: 29867548; PMCID: PMC5962745.
  10. Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, Chandarlapaty S, Arribas J, Bellet M, Serra V, Aloy P. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Med. 2020 Sep 9;12(1):78. doi: 10.1186/s13073-020-00774-x. PMID: 32907621; PMCID: PMC7488324.

Top Experts on “nanotechnology“